Oncopeptides publishes the 2024 Annual Report
April 28, 2025 Regulatory
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the 2024 Annual Report has been published.
”2024 was a transformative year for Oncopeptides as we continued our journey toward sustainable growth and expanded access to Pepaxti. Over the past year, we have made significant strides in commercialization, market access, and pipeline development, laying the foundation for long-term success,” says Sofia Heigis, CEO of Oncopeptides. “With the progress made in 2024, I am confident that we are on the path to making a meaningful impact on patients worldwide and becoming a profitable company by the end of 2026 in line with our goals.”
The Annual Report for 2024 is available on Oncopeptides’ website under financial reports.
For more information, please contact:
David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)
E-mail: ir@oncopeptides.com
Cell phone: +46 76 229 38 68
This information is information that Oncopeptides is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-28 15:30 CEST.
About Oncopeptides
Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.
The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.
Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.
The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.
For more information see: www.oncopeptides.com
